

July 19, 2019

Sumitomo Dainippon Pharma Co., Ltd.

**Comments on Announcement by Australian Stem Cell and  
Regenerative Medicine Company**

Cynata Therapeutics Limited (Head office: Australia), an Australian stem cell and regenerative medicine company, announced on July 19 that Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) has entered into a negotiation to acquire Cynata.

Please refer to the link below for the press release of Cynata.  
(<https://www.asx.com.au/asxpdf/20190719/pdf/446qrm8wqhrf97.pdf>)

While Sumitomo Dainippon Pharma has made the proposal for the acquisition of Cynata and is negotiating with Cynata, no formal decision has been made at this moment. Sumitomo Dainippon Pharma will make an announcement in a timely manner if we decide any matter which needs to be disclosed.

Contact:  
Corporate Communications  
Sumitomo Dainippon Pharma Co., Ltd.  
TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)